B. Metzler Seel. Sohn & Co. Ag Bio N Tech Se Transaction History

B. Metzler Seel. Sohn & Co. Ag

$10 Billion
Q3 2024

A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Bio N Tech Se stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 9,468 shares of BNTX stock, worth $964,505. This represents 0.01% of its overall portfolio holdings.

Number of Shares

9,468

Previous 8,004 18.29%

Holding current value

$964,505

Previous $643,000 74.81%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$78.36 - $124.66 $114,719 - $182,502	1,464 Added 18.29%	9,468 $1.12 Million
Q2 2024 Aug 13, 2024	SELL	$80.36 - $102.87 $439,729 - $562,904	-5,472 Reduced 40.61%	8,004 $643,000
Q1 2024 May 15, 2024	BUY	$88.96 - $112.35 $316,163 - $399,291	3,554 Added 35.82%	13,476 $1.24 Million
Q3 2023 Nov 13, 2023	BUY	$98.5 - $125.08 $39,400 - $50,032	400 Added 4.2%	9,922 $1.08 Million
Q2 2023 Aug 11, 2023	SELL	$102.58 - $129.66 $148,228 - $187,358	-1,445 Reduced 13.18%	9,522 $1.03 Million
Q1 2023 May 10, 2023	BUY	$122.57 - $153.67 $18,385 - $23,050	150 Added 1.39%	10,967 $1.37 Million
Q4 2022 Feb 13, 2023	BUY	$118.43 - $186.05 $4,145 - $6,511	35 Added 0.32%	10,817 $1.62 Million
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $140,159 - $201,054	-1,098 Reduced 9.24%	10,782 $1.45 Million
Q2 2022 Aug 12, 2022	SELL	$123.25 - $186.24 $328,461 - $496,329	-2,665 Reduced 18.32%	11,880 $1.77 Million
Q1 2022 May 10, 2022	BUY	$126.25 - $231.85 $1.52 Million - $2.79 Million	12,050 Added 482.97%	14,545 $2.48 Million
Q4 2021 Feb 11, 2022	BUY	$216.64 - $362.52 $540,516 - $904,487	2,495 New	2,495 $600,000

Others Institutions Holding BNTX

# of Institutions

357

Shares Held

38.4M

Call Options Held

2.45M

Put Options Held

2.29M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $24.7B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

News

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.

Account

B. Metzler Seel. Sohn & Co. Ag Bio N Tech Se Transaction History